ARTICLE | Distillery Therapeutics


December 6, 2016 7:37 PM UTC

Mouse studies suggest inhibiting signaling between IL-33 and IL1RL1 could help treat poison ivy-induced allergic dermatitis. A mouse model of poison ivy-induced dermatitis had high levels of IL-33 in the skin. In the model, siRNA targeting IL1RL1 or antibodies against IL-33 or IL1RL1 decreased skin inflammation and scratching behavior compared with scrambled siRNA or control antibodies. Next steps include testing levels of IL-33 and IL1RL1 in human skin cells exposed to poison ivy toxins.

Amgen Inc., Roche and its Genentech Inc. unit have AMG282 (RG6149), an antibody that inhibits the binding of IL-33 to IL1RL1, in Phase I testing to treat asthma...